Integrity Applications, Inc. (OTCMKTS:IGAP) Files An 8-K Regulation FD Disclosure

Integrity Applications, Inc. (OTCMKTS:IGAP) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure

Story continues below

On September 26, 2017,management of Integrity Applications, Inc. (the “Company”) gave a presentation related to the business and performance of the Company at the Redefining Early Stage Investments Conference in Boston, MA.

A copy of the presentation slides presented at the conference is attached hereto as Exhibit 99.1. The information contained in this item and the exhibit attached herewith shall be deemed furnished and not filed. The information contained in the presentation slides has been provided for information purposes only and should not be construed as an offer to sell or a solicitation of an offer to purchase any of the Company’s securities.

Section 9 – Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits



Presentation Slides, dated September 26, 2017

Integrity Applications, Inc. Exhibit
EX-99.1 2 exhibit_99-1.htm EXHIBIT 99.1 Exhibit 99.1                  GlucoTrackA First In Class Non-Invasive GlucoseMonitoring Platform  Digital Health SolutionSupporting healthy behaviors by providingindividual context to glucose data    The Integrity Applications Growth Story               Attractive Industry Dynamics Glucose monitoring undergoing rapid disruptive change      Forward-Looking Statements  This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing,…
To view the full exhibit click here

About Integrity Applications, Inc. (OTCMKTS:IGAP)

Integrity Applications, Inc. is a medical device company. The Company is focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by persons suffering from diabetes. It has developed a non-invasive blood glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes obtain blood glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot finger stick devices. The Company operates in Europe, and Asia and Pacific. The GlucoTrack model DF-F utilizes a combination of ultrasound, electromagnetic and thermal technologies to obtain blood glucose measurements in less than one minute through a small sensor that is clipped onto one’s earlobe and connected to a small, handheld control and display unit, all without drawing blood.

An ad to help with our costs